NCT05733546View on ClinicalTrials.gov

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Major Depressive Disorder
Interventions
DRUG

Psilocybin

COMP360 Psilocybin administered under supportive conditions

Trial Locations (5)

20850

Sunstone Therapies, Rockville

32256

Clinical Neuroscience Solutions Inc, Jacksonville

75093

Aims Trial, Plano

92037

Kadima Neuropsychiatry Institute, La Jolla

01103

Elixia MA, LLC, Springfield

Sponsors

Lead Sponsor

COMPASS Pathways
All Listed Sponsors
lead

COMPASS Pathways

INDUSTRY